Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980 to Filter to 202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980

---

Search results

• Journal article
  Weiss B, Sleep CE, Beller NM, Erritzoe D, Campbell WKet al., 2023,

  Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

  , JOURNAL OF PSYCHEDELIC STUDIES, Vol: 7, Pages: 200-226
  • Cite
• Conference paper
  Erritzoe D, 2023,

  Keynote Lecture 2 "Psychedelics in mental health - therapeutic potential and possible brain mechanisms"

  , 71st International Congress and Annual Meeting of the Society-for-Medicinal-Plant-and-Natural-Product-Research, Publisher: GEORG THIEME VERLAG KG, Pages: 1284-1284, ISSN: 0032-0943
  • Cite
• Journal article
  Nutt DJ, 2023,

  Pharmacological Dissection of Antipsychotics

  , BIOLOGICAL PSYCHIATRY, Vol: 94, Pages: 524-525, ISSN: 0006-3223
  • Author Web Link
  • Cite
• Journal article
  Wall MB, Harding R, Zafar R, Rabiner EA, Nutt DJ, Erritzoe Det al., 2023,

  Neuroimaging in psychedelic drug development: past, present, and future

  , MOLECULAR PSYCHIATRY, ISSN: 1359-4184
  • Author Web Link
  • Cite
• Journal article
  Bremler R, Katati N, Shergill P, Erritzoe D, Carhart-Harris Ret al., 2023,

  Case analysis of long-term negative psychological responses to psychedelics

  , Scientific Reports, Vol: 13, Pages: 1-15, ISSN: 2045-2322

  Recent controversies have arisen regarding claims of uncritical positive regard and hype surrounding psychedelic drugs and their therapeutic potential. Criticisms have included that study designs and reporting styles bias positive over negative outcomes. The present study was motivated by a desire to address this alleged bias by intentionally focusing exclusively on negative outcomes, defined as self-perceived ‘negative’ psychological responses lasting for at least 72 h after psychedelic use. A strong justification for this selective focus was that it might improve our ability to capture otherwise missed cases of negative response, enabling us to validate their existence and better examine their nature, as well as possible causes, which could inspire risk-mitigation strategies. Via advertisements posted on social media, individuals were recruited who reported experiencing negative psychological responses to psychedelics (defined as classic psychedelics plus MDMA) lasting for greater than 72 h since using. Volunteers were directed to an online questionnaire requiring quantitative and qualitative input. A key second phase of this study involved reviewing all of the submitted cases, identifying the most severe—e.g., where new psychiatric diagnoses were made or pre-existing symptoms made worse post psychedelic-use—and inviting these individuals to participate in a semi-structured interview with two members of our research team, during which participant experiences and backgrounds were examined in greater depth. Based on the content of these interviews, a brief summary of each case was compiled, and an explorative thematic analysis was used to identify salient and consistent themes and infer common causes. 32 individuals fully completed an onboarding questionnaire (56% male, 53% < age 25); 37.5% of completers had a psychiatric diagnosis that emerged after their psychedelic experience, and anxiety symptoms arose or worsened in 87%.

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite
• Journal article
  Garel N, Drury J, Levesque JT, Goyette N, Lehmann A, Looper K, Erritzoe D, Dames S, Turecki G, Rej S, Richard-Devantoy S, Greenway KTet al., 2023,

  The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression

  , FRONTIERS IN PSYCHIATRY, Vol: 14, ISSN: 1664-0640
  • Author Web Link
  • Cite
• Journal article
  Murphy RJ, Sumner R, Evans W, Ponton R, Ram S, Godfrey K, Forsyth A, Cavadino A, Naga VK, Smith T, Hoeh NR, Menkes DB, Muthukumaraswamy Set al., 2023,

  Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial

  , BIOLOGICAL PSYCHIATRY, Vol: 94, Pages: 511-521, ISSN: 0006-3223
  • Author Web Link
  • Cite
  • Citations: 5
• Journal article
  Eckernas E, Koomen J, Timmermann C, Carhart-Harris R, Roshammar D, Ashton Met al., 2023,

  Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework

  , CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, ISSN: 2163-8306
  • Author Web Link
  • Cite
• Journal article
  Simonsson O, Carlbring P, Carhart-Harris R, Davis AK, Nutt DJ, Griffiths RR, Erritzoe D, Goldberg SBet al., 2023,

  Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis

  , PSYCHIATRY RESEARCH, Vol: 327, ISSN: 0165-1781
  • Author Web Link
  • Cite
• Journal article
  Thurgur H, Schlag AK, Iveson E, Hosseini A, Lynskey M, Nutt DJet al., 2023,

  Cannabis-based medicinal products (CBMPs) for the treatment of Long COVID symptoms: current and potential applications

  , Exploration of Medicine, Pages: 487-503

  <jats:p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can result in a range of persistent symptoms impacting everyday functioning for a considerable proportion of patients, a condition termed Long coronavirus disease (COVID) or post COVID-19 syndrome. The severity and set of symptoms vary between patients, and include fatigue, cognitive dysfunction, sleep disturbances, palpitations, tachycardia, pain, depression, and anxiety. The high prevalence of Long COVID combined with the lack of treatment approaches has resulted in considerable unmet clinical needs. There is a growing body of evidence that cannabis-based medicinal products (CBMPs) can be used to treat symptoms including pain, anxiety, depression, fatigue, sleep, headaches, and cognitive dysfunction, which are commonly reported in Long COVID. This article provides an overview of the pathophysiology of Long COVID and discusses preliminary pre-clinical, clinical trials, and real-world evidence (RWE) for CBMPs in the context of Long COVID. This review summarises current clinical trials and studies exploring CBMPs in Long COVID. The current evidence provides a rationale to further explore CBMPs as a treatment for Long COVID symptoms. In addition to further randomised controlled trials (RCTs), the increasing availability of CBMPs globally, coupled with the continued prevalence of Long COVID in the population, also highlights the value of real-world data in the research of CBMPs in Long COVID. Critically, there is an evident need for multidisciplinary approaches of CBMPs and Long COVID in real-world clinical practice settings.</jats:p>

  • Abstract
  • Publisher Web Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.